109 related articles for article (PubMed ID: 19663741)
21. [Pharmacotherapy of a geriatric patient with Parkinson's disease].
Klemmer JM; Schmitz S; Roth S; Simons S; Reineking N; Eisert A; Lang B; Jaehde U
Med Monatsschr Pharm; 2007 Nov; 30(11):411-4. PubMed ID: 18062332
[TBL] [Abstract][Full Text] [Related]
22. Importance of P-glycoprotein at blood-tissue barriers.
Fromm MF
Trends Pharmacol Sci; 2004 Aug; 25(8):423-9. PubMed ID: 15276711
[TBL] [Abstract][Full Text] [Related]
23. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population.
Jeannesson E; Albertini L; Siest G; Gomes AM; Ribeiro V; Aslanidis C; Schmitz G; Visvikis-Siest S
Fundam Clin Pharmacol; 2007 Aug; 21(4):411-8. PubMed ID: 17635180
[TBL] [Abstract][Full Text] [Related]
24. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.
Marzolini C; Paus E; Buclin T; Kim RB
Clin Pharmacol Ther; 2004 Jan; 75(1):13-33. PubMed ID: 14749689
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction.
Sun J; He ZG; Cheng G; Wang SJ; Hao XH; Zou MJ
Med Sci Monit; 2004 Jan; 10(1):RA5-14. PubMed ID: 14704647
[TBL] [Abstract][Full Text] [Related]
27. [New pharmacologic strategies for the treatment of Parkinson disease].
Tolosa E; Molinuevo JL; Valldeoriola F; Pastor P
Neurologia; 1999 May; 14 Suppl 1():46-53. PubMed ID: 10377729
[TBL] [Abstract][Full Text] [Related]
28. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection.
Barnard JB; Richardson S; Sheldon S; Fildes J; Pravica V; Hutchinson IV; Leonard CT; Yonan N
Transplantation; 2006 Dec; 82(12):1677-82. PubMed ID: 17198259
[TBL] [Abstract][Full Text] [Related]
29. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
30. The history of drugs for the treatment of Parkinson's disease.
Kapp W
J Neural Transm Suppl; 1992; 38():1-6. PubMed ID: 1491242
[TBL] [Abstract][Full Text] [Related]
31. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
Frey KA
Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500
[No Abstract] [Full Text] [Related]
32. Levodopa for Parkinson's disease.
Gérard JM; Elosegi JA
N Engl J Med; 2009 Feb; 360(9):936; author reply 936. PubMed ID: 19256032
[No Abstract] [Full Text] [Related]
33. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery.
Varma MV; Perumal OP; Panchagnula R
Curr Opin Chem Biol; 2006 Aug; 10(4):367-73. PubMed ID: 16814593
[TBL] [Abstract][Full Text] [Related]
34. ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.
Aird RE; Thomson M; Macpherson JS; Thurston DE; Jodrell DI; Guichard SM
Pharmacogenomics J; 2008 Aug; 8(4):289-96. PubMed ID: 17563765
[TBL] [Abstract][Full Text] [Related]
35. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation.
Asanuma M; Miyazaki I
Expert Rev Neurother; 2006 Sep; 6(9):1313-25. PubMed ID: 17009919
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
37. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics.
Staud F; Ceckova M; Micuda S; Pavek P
Methods Mol Biol; 2010; 596():199-222. PubMed ID: 19949926
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
39. Novel and functional ABCB1 gene variant in sporadic Parkinson's disease.
Li Y; Li Y; Pang S; Huang W; Zhang A; Hawley RG; Yan B
Neurosci Lett; 2014 Apr; 566():61-6. PubMed ID: 24572589
[TBL] [Abstract][Full Text] [Related]
40. ABCB1: is there a role in the drug treatment of Parkinson's disease?
Müller T
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):127-129. PubMed ID: 29224383
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
